 SAN FRANCISCO, July 15, 2021 GLOBE NEWSWIRE -- FibroGen, Inc. NASDAQ: FGEN today announced that the U.S. Food and Drug Administration FDA Cardiovascular and Renal Drugs Advisory Committee CRDAC voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase HIF-PH inhibitor, for the treatment of anemia due to chronic kidney disease CKD in adult patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committees vote, the agency considers the Committees non-binding recommendations when making its decision. 